FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, particularly to a combination for treating cancer comprising at least 1) a fusion protein comprising a portion specifically recognizing EDb-fibronectin representing an antibody, and a portion representing interleukine-2 and 2) a molecule that binds to B-cells, B-cell precursors and/or their cancerous counterpart which is an antibody or antibody or an antibody fragment specifically binding to CD-20. What is also declared is the use of this combination.
EFFECT: group of inventions provides higher clinical effectiveness in treating a tumour.
23 cl, 1 tbl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| IMMUNOTHERAPY OF MALIGNANT DISEASES OF B-CELLS AND AUTOIMMUNE DISEASES WITH APPLICATION OF CONJUGATE AND NONCONJUGATE ANTIBODIES, COMBINATIONS OF ANTIBODIES AND CONJOINT PROTEINS | 2003 |
|
RU2335297C2 |
| METHOD FOR UPREGULATING ANTIGEN EXPRESSION | 2014 |
|
RU2681953C2 |
| IMMUNOCYTOCINS COMBINED THERAPY | 2012 |
|
RU2628089C2 |
| DECREASING B-CELL COUNT WITH USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2423381C2 |
| TREATMENT OF B-CELLULAR MALIGNANT TUMORS USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR BY CHEMOTHERAPY AND RADIOTHERAPY | 2000 |
|
RU2305561C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-R[ALPHA] SUSHI DOMAIN | 2012 |
|
RU2644671C2 |
| CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2011 |
|
RU2602878C2 |
| CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2016 |
|
RU2678818C2 |
